P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)

Detalles Bibliográficos
Autores principales: Hernandez-Ilizaliturri, F. J., Kuruvilla, J., Christian, B. A., Flinn, I. W., Assouline, S. E., Ulrickson, M. L., Landsburg, D. J., Stuart, M., Lowman, H., Levin, N., Maetzel, D., Viller, N. N., MacLaren, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430507/
http://dx.doi.org/10.1097/01.HS9.0000847476.69621.cd

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430507/
http://dx.doi.org/10.1097/01.HS9.0000847476.69621.cd

Ejemplares similares